{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:09:07Z","timestamp":1789171747430,"version":"build-2803163510"},"reference-count":69,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.clinthera.2021.03.005","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T06:22:42Z","timestamp":1617258162000},"page":"e86-e102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Influence of Genetic Polymorphisms on the Response to Tramadol, Ibuprofen, and the Combination in Patients With Moderate to Severe Pain After Dental Surgery"],"prefix":"10.1016","volume":"43","author":[{"given":"Miriam","family":"Saiz-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah\u00ed","family":"Valdez-Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto M.","family":"Borobia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Burgue\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"G\u00e1lvez-M\u00fagica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Acero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Cabaleiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Fernando","family":"Mu\u00f1oz-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Puerro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Llanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Mart\u00ednez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio J.","family":"Carcas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clinthera.2021.03.005_bib0001","first-page":"203","article-title":"Update and review on the basics of pain management","volume":"16","author":"Al-Sayed","year":"2011","journal-title":"Neurosci Riyadh Saudi Arab"},{"issue":"8","key":"10.1016\/j.clinthera.2021.03.005_bib0002","first-page":"1146","article-title":"Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes","volume":"29","author":"Subrahmanyam","year":"2001","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"8","key":"10.1016\/j.clinthera.2021.03.005_bib0003","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/BF00180294","article-title":"The metabolism of tramadol by human liver microsomes","volume":"70","author":"Paar","year":"1992","journal-title":"Clin Investig"},{"issue":"3\u20134","key":"10.1016\/j.clinthera.2021.03.005_bib0004","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s002280050368","article-title":"Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol","volume":"53","author":"Paar","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.clinthera.2021.03.005_bib0005","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/FPC.0000000000000057","article-title":"PharmGKB summary: tramadol pathway","volume":"24","author":"Gong","year":"2014","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"10.1016\/j.clinthera.2021.03.005_bib0006","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2165\/00002018-199615010-00002","article-title":"A risk-benefit assessment of tramadol in the management of pain","volume":"15","author":"Radbruch","year":"1996","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.clinthera.2021.03.005_bib0007","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0022-3565(24)38909-8","article-title":"Modeling of the in vivo antinociceptive interaction between an opioid agonist, (+)-O-desmethyltramadol, and a monoamine reuptake inhibitor, (-)-O-desmethyltramadol, in rats","volume":"295","author":"Garrido","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.clinthera.2021.03.005_bib0008","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/00003495-200060010-00008","article-title":"Tramadol: a review of its use in perioperative pain","volume":"60","author":"Scott","year":"2000","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.clinthera.2021.03.005_bib0009","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s002100000266","article-title":"Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor","volume":"362","author":"Gillen","year":"2000","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"13","key":"10.1016\/j.clinthera.2021.03.005_bib0010","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200443130-00004","article-title":"Clinical pharmacology of tramadol","volume":"43","author":"Grond","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.clinthera.2021.03.005_bib0011","first-page":"827","article-title":"Tramadol: basic pharmacology and emerging concepts","volume":"44","author":"Reeves","year":"2008","journal-title":"Drugs Today Barc Spain 1998"},{"issue":"1","key":"10.1016\/j.clinthera.2021.03.005_bib0012","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0022-3565(25)39454-1","article-title":"Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol","volume":"267","author":"Raffa","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2021.03.005_bib0013","series-title":"CYP2D6 allele nomenclature","year":"2021"},{"issue":"2","key":"10.1016\/j.clinthera.2021.03.005_bib0014","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","article-title":"The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype","volume":"83","author":"Gaedigk","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.clinthera.2021.03.005_bib0015","first-page":"215","article-title":"Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)","volume":"19","author":"Caudle","year":"2017","journal-title":"Genet Med Off J Am Coll Med Genet"},{"issue":"1","key":"10.1016\/j.clinthera.2021.03.005_bib0016","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.clpt.6100152","article-title":"Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes","volume":"82","author":"Stamer","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.clinthera.2021.03.005_bib0017","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.phrs.2006.11.003","article-title":"Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype","volume":"55","author":"Garc\u00eda-Quetglas","year":"2007","journal-title":"Pharmacol Res"},{"issue":"6","key":"10.1016\/j.clinthera.2021.03.005_bib0018","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0009-9236(96)90211-8","article-title":"The hypoalgesic effect of tramadol in relation to CYP2D6","volume":"60","author":"Poulsen","year":"1996","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.clinthera.2021.03.005_bib0019","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1136\/ard.2009.124347","article-title":"Adverse events in analgesic treatment with tramadol associated with CYP2D6 extensive-metaboliser and OPRM1 high-expression variants","volume":"69","author":"Kim","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.clinthera.2021.03.005_bib0020","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1213\/01.ane.0000189613.61910.32","article-title":"The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6","volume":"102","author":"Enggaard","year":"2006","journal-title":"Anesth Analg"},{"key":"10.1016\/j.clinthera.2021.03.005_bib0021","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.forsciint.2014.03.003","article-title":"Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose","volume":"238","author":"Bastami","year":"2014","journal-title":"Forensic Sci Int"},{"issue":"1\u20132","key":"10.1016\/j.clinthera.2021.03.005_bib0022","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0304-3959(03)00212-4","article-title":"Impact of CYP2D6 genotype on postoperative tramadol analgesia","volume":"105","author":"Stamer","year":"2003","journal-title":"Pain"},{"issue":"11","key":"10.1016\/j.clinthera.2021.03.005_bib0023","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00228-006-0191-2","article-title":"Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population","volume":"62","author":"Wang","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.clinthera.2021.03.005_bib0024","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/JCP.0b013e318160f827","article-title":"Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol","volume":"28","author":"Kirchheiner","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2021.03.005_bib0025","first-page":"179","article-title":"CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort","volume":"11","author":"Dagostino","year":"2018","journal-title":"Pharmacogenomics Pers Med"},{"key":"10.1016\/j.clinthera.2021.03.005_bib0026","first-page":"71","article-title":"Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics","volume":"13","author":"Lopes","year":"2020","journal-title":"Pharmacogenomics Pers Med"},{"issue":"11","key":"10.1016\/j.clinthera.2021.03.005_bib0027","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1097\/j.pain.0000000000000662","article-title":"Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption","volume":"157","author":"Stamer","year":"2016","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.clinthera.2021.03.005_bib0028","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.clpt.6100095","article-title":"Pharmacogenetics of opioids","volume":"81","author":"Somogyi","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2021.03.005_bib0029","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pbb.2013.10.018","article-title":"Pharmacogenetics of OPRM1","volume":"123","author":"Crist","year":"2014","journal-title":"Pharmacol Biochem Behav"},{"issue":"5","key":"10.1016\/j.clinthera.2021.03.005_bib0030","first-page":"1393","article-title":"Expression changes in arrestin \u03b2 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients","volume":"27","author":"Matsuoka","year":"2012","journal-title":"Oncol Rep"},{"issue":"10","key":"10.1016\/j.clinthera.2021.03.005_bib0031","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jpain.2013.04.006","article-title":"An opposite-direction modulation of the COMT Val158Met polymorphism on the clinical response to intrathecal morphine and triptans","volume":"14","author":"Cargnin","year":"2013","journal-title":"J Pain Off J Am Pain Soc"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2021.03.005_bib0032","first-page":"S78","article-title":"Anti-inflammatory drugs and their mechanism of action","volume":"47","author":"Vane","year":"1998","journal-title":"Inflamm Res Off J Eur Histamine Res Soc Al"},{"issue":"2","key":"10.1016\/j.clinthera.2021.03.005_bib0033","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/FPC.0000000000000113","article-title":"PharmGKB summary: ibuprofen pathways","volume":"25","author":"Mazaleuskaya","year":"2015","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"10.1016\/j.clinthera.2021.03.005_bib0034","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003088-199834020-00002","article-title":"Clinical pharmacokinetics of ibuprofen. The first 30 years","volume":"34","author":"Davies","year":"1998","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.clinthera.2021.03.005_bib0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1081\/DMR-200047999","article-title":"Enantioselective pharmacokinetics of ibuprofen and involved mechanisms","volume":"37","author":"Hao","year":"2005","journal-title":"Drug Metab Rev"},{"issue":"11","key":"10.1016\/j.clinthera.2021.03.005_bib0036","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1211\/jpp.59.11.0007","article-title":"Effect of absorption rate on pharmacokinetics of ibuprofen in relation to chiral inversion in humans","volume":"59","author":"Ding","year":"2007","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"10.1016\/j.clinthera.2021.03.005_bib0037","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0022-3565(25)20501-8","article-title":"Stereoselective metabolism of ibuprofen in humans: administration of R-, S- and racemic ibuprofen","volume":"259","author":"Rudy","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.clinthera.2021.03.005_bib0038","first-page":"189","article-title":"A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs","volume":"19","author":"Leemann","year":"1993","journal-title":"Drugs Exp Clin Res"},{"issue":"1","key":"10.1016\/j.clinthera.2021.03.005_bib0039","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0006-2952(97)00143-3","article-title":"Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C","volume":"54","author":"Hamman","year":"1997","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.clinthera.2021.03.005_bib0040","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00228-007-0273-9","article-title":"Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen","volume":"63","author":"Tornio","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.clinthera.2021.03.005_bib0041","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2125.1995.tb05769.x","article-title":"Lack of effect of gender and oral contraceptive steroids on the pharmacokinetics of (R)-ibuprofen in humans","volume":"40","author":"Knights","year":"1995","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.clinthera.2021.03.005_bib0042","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0090-9556(24)15081-7","article-title":"Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s","volume":"28","author":"McGinnity","year":"2000","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"12","key":"10.1016\/j.clinthera.2021.03.005_bib0043","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1124\/dmd.108.022970","article-title":"Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro","volume":"36","author":"Chang","year":"2008","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"10.1016\/j.clinthera.2021.03.005_bib0044","series-title":"CYP2C8 allele nomenclature","year":"2021"},{"key":"10.1016\/j.clinthera.2021.03.005_bib0045","unstructured":"The Pharmacogene Variation (PharmVar) Consortium. CYP2C9 allele nomenclature. Last accessed July 27, 2018. Available from: https:\/\/www.pharmvar.org\/gene\/CYP2C9."},{"issue":"1","key":"10.1016\/j.clinthera.2021.03.005_bib0046","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF03256440","article-title":"Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals","volume":"10","author":"Garc\u00eda-Mart\u00edn","year":"2006","journal-title":"Mol Diagn Ther"},{"issue":"3","key":"10.1016\/j.clinthera.2021.03.005_bib0047","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00008571-200204000-00010","article-title":"Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data","volume":"12","author":"Lee","year":"2002","journal-title":"Pharmacogenetics"},{"issue":"6","key":"10.1016\/j.clinthera.2021.03.005_bib0048","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/00498250902862705","article-title":"Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes","volume":"39","author":"Kara\u017aniewicz-\u0141ada","year":"2009","journal-title":"Xenobiotica Fate Foreign Compd Biol Syst"},{"issue":"1","key":"10.1016\/j.clinthera.2021.03.005_bib0049","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2125.2004.02183.x","article-title":"The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects","volume":"59","author":"Mart\u00ednez","year":"2005","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.clinthera.2021.03.005_bib0050","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1067\/mcp.2002.125726","article-title":"Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2","volume":"72","author":"Kirchheiner","year":"2002","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.clinthera.2021.03.005_bib0051","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.phrs.2008.07.004","article-title":"Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers","volume":"58","author":"L\u00f3pez-Rodr\u00edguez","year":"2008","journal-title":"Pharmacol Res"},{"issue":"9","key":"10.1016\/j.clinthera.2021.03.005_bib0052","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2217\/pgs.15.40","article-title":"Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers","volume":"16","author":"Ochoa","year":"2015","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.clinthera.2021.03.005_bib0053","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cpt.1830","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs","volume":"108","author":"Theken","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.clinthera.2021.03.005_bib0054","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/cts.12526","article-title":"Clinical Implementation of Pharmacogenetic Testing in a Hospital of the Spanish National Health System: Strategy and Experience Over 3 Years","volume":"11","author":"Borobia","year":"2018","journal-title":"Clin Transl Sci"},{"issue":"3","key":"10.1016\/j.clinthera.2021.03.005_bib0055","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/tpj.2014.67","article-title":"High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme","volume":"15","author":"Apell\u00e1niz-Ruiz","year":"2015","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"10.1016\/j.clinthera.2021.03.005_bib0056","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/bcpt.12960","article-title":"Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers","volume":"122","author":"Belmonte","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"10.1016\/j.clinthera.2021.03.005_bib0057","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat Protoc"},{"issue":"1","key":"10.1016\/j.clinthera.2021.03.005_bib0058","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/cts.12692","article-title":"Standardizing CYP 2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group","volume":"13","author":"Caudle","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.clinthera.2021.03.005_bib0059","unstructured":"Hardy-Weinberg equilibrium. Last accessed February, 2020. Available from: http:\/\/ihg.gsf.de\/cgi-bin\/hw\/hwa1.pl."},{"issue":"7571","key":"10.1016\/j.clinthera.2021.03.005_bib0060","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.clinthera.2021.03.005_bib0061","first-page":"79","article-title":"Tramadol and acetaminophen tablets for dental pain","volume":"48","author":"Medve","year":"2001","journal-title":"Anesth Prog"},{"issue":"5","key":"10.1016\/j.clinthera.2021.03.005_bib0062","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.clpt.2006.01.013","article-title":"Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs","volume":"79","author":"Lee","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2021.03.005_bib0063","unstructured":"Dutch Pharmacogenetics Working Group. Annotation of DPWG Guideline for tramadol and CYP2D6. Avaiblae from: https:\/\/www.pharmgkb.org\/guidelineAnnotation\/PA166104959 Last accessed 31 July, 2020."},{"issue":"10","key":"10.1016\/j.clinthera.2021.03.005_bib0064","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2217\/pgs-2020-0026","article-title":"Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics","volume":"21","author":"Saiz-Rodr\u00edguez","year":"2020","journal-title":"Pharmacogenomics"},{"issue":"0","key":"10.1016\/j.clinthera.2021.03.005_bib0065","article-title":"The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor","volume":"0","author":"Kroslak","year":"2007","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/j.clinthera.2021.03.005_bib0066","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1365-2044.2009.06193.x","article-title":"Association of human \u00ce\u00bc-opioid receptor gene polymorphism A118G with fentanyl analgesia consumption in Chinese gynaecological patients","volume":"65","author":"Zhang","year":"2010","journal-title":"Anaesthesia"},{"issue":"4","key":"10.1016\/j.clinthera.2021.03.005_bib0067","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2344\/0003-3006-57.4.145","article-title":"Diversity of Opioid Requirements for Postoperative Pain Control Following Oral Surgery\u2014Is It Affected by Polymorphism of the \u03bc-Opioid Receptor?","volume":"57","author":"Fukuda","year":"2010","journal-title":"Anesth Prog"},{"issue":"4","key":"10.1016\/j.clinthera.2021.03.005_bib0068","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/sj.clpt.6100385","article-title":"Association of ABCB1\/MDR1 and OPRM1 Gene Polymorphisms With Morphine Pain Relief","volume":"83","author":"Campa","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.clinthera.2021.03.005_bib0069","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/cncr.26430","article-title":"Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol\/acetaminophen combination tablets (ultracet) in oxaliplatin-induced painful neuropathy","volume":"118","author":"Liu","year":"2012","journal-title":"Cancer"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821001132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821001132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:55:56Z","timestamp":1758963356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821001132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0149291821001132"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.03.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of Genetic Polymorphisms on the Response to Tramadol, Ibuprofen, and the Combination in Patients With Moderate to Severe Pain After Dental Surgery","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}